In the first case, a reversible covalent attachment of a diketone compound is achieved through the formation of an imine, which isomerizes to the more stable enaminone derivative. In the latter case, an acetone aldol adduct of the vinylketone is used as a prolinker, because the vinylketone linker is highly reactive. mAb 38C2 catalyzes the retro-aldol reaction of the prolinker to give free vinylketone linker, which then undergoes Michael addition, in situ, with the catalytic Lys residue in the antibody-binding site. This approach provides irreversible attachment of the targeting modules; however, preparation of the prolinker equipped targeting modules requires complicated multistep synthesis and is not compatible with a wide range of substrates. In earlier studies we had explored a b-lactam-based modification strategy for covalent attachment of thiazolium cofactor into the active site of aldolase antibodies in order to prepare the first thiazolium-dependent catalytic antibodies.
Monoclonal antibody (mAb) 38C2 was generated by reactive immunization with a 1,3-diketone hapten. 1 This antibody possesses a lysine residue at position 93 of the heavy chain, LysH93, that has an unusually low pK a of 6.0 and is essential for the catalytic mechanism of the antibody. 2 [3] [4] [5] [6] [7] In the first case, a reversible covalent attachment of a diketone compound is achieved through the formation of an imine, which isomerizes to the more stable enaminone derivative. In the latter case, an acetone aldol adduct of the vinylketone is used as a prolinker, because the vinylketone linker is highly reactive. mAb 38C2 catalyzes the retro-aldol reaction of the prolinker to give free vinylketone linker, which then undergoes Michael addition, in situ, with the catalytic Lys residue in the antibody-binding site. This approach provides irreversible attachment of the targeting modules; however, preparation of the prolinker equipped targeting modules requires complicated multistep synthesis and is not compatible with a wide range of substrates. In earlier studies we had explored a b-lactam-based modification strategy for covalent attachment of thiazolium cofactor into the active site of aldolase antibodies in order to prepare the first thiazolium-dependent catalytic antibodies. 9 Given the success of this study and the chemical stability of the resulting covalent modification, we were encouraged to examine this approach as a route to chemically programmed antibodies. Here we report the selective reaction of the catalytic site LysH93 with b-lactam-equipped targeting modules (Scheme 1C); the synthesis of the targeting module was straightforward and this strategy provides for irreversible covalent attachment of targeting modules. We 9 Second, the narrow and highly lipophilic catalytic site of mAb 38C2 should bind tightly to a phenyl ring based on the crystal structure of the antibody. 2 Third,
given the disposition of LysH93 at the bottom of the 11-Å deep active site, a linker of appropriate length should be incorporated to allow functional display of the targeting module outside the active site of the antibody. The heterobifunctional b-lactam targeting module 3 was synthesized in six steps starting from inexpensive starting materials. In brief, 2-(2-(2-chloroethoxy)ethoxy)ethanol 1 was treated with sodium azide in DMF to afford the corresponding azido alcohol in 89% yield (Scheme 2). Subsequent tosylation provided tosyl azide 2 in quantitative yield. Reaction of 2 with ethyl 4-hydroxybenzoate in the presence of potassium carbonate in DMF provided azido ester in 76% isolated yield. The ester was hydrolyzed using lithium hydroxide followed by a reaction with neat thionyl chloride to give the corresponding acid chloride. The crude acid chloride was used immediately for the reaction with 2-azetidinone in the presence of n-butyl lithium to afford the desired heterobifunctional module 3 in 44% isolated yield.
We selected biotin as a model targeting module to evaluate the b-lactam-based approach for chemical programming of mAb 38C2. Biotin containing 6 was prepared as follows: biotin N-hydroxysuccinimide ester 4 was coupled with propargyl amine to give alkynyl biotin 5 in 96% yield (Scheme 3).
The subsequent copper (I)-catalyzed azide alkyne cycloaddition reaction [10] [11] [12] [13] [14] [15] of b-lactam module 3 and alkyne 5 furnished the desired targeting module 6 in 87% isolated yield. Chemical programming of the mAb 38C2 with 6 was performed essentially as described. 3 Only 2 equiv of the targeting module 6
were used (1 equiv per active site) and complete loss of catalytic activity of mAb 38C2 was observed after 2 h at room temperature. Catalytic activity was measured by analysis of the retro-aldol reaction of methodol (Fig. 1A) . 3 Aliquots were removed at different timepoints and the reaction was quenched by immediate removal of any unbound small molecules by desalting using Zeba spin desalting columns (Pierce Inc.); the resulting purified antibody was tested in the methodol-based catalytic activity assay. MAL-DI-TOF analysis of the biotin programmed mAb 38C2 compared to that of mAb 38C2 gave an additional proof of the selective functionalization of catalytic site LysH93 in the context of the IgG (Fig. 1B) . 9 Analysis of tryptic digests confirmed LysH93 labeling.
To confirm that the chemically programmed antibody displayed biotin in a manner to allow for its binding to streptavidin, we also used a streptavidin ELISA (Fig. 1C) . We then chemically programmed the antibody to recognize integrin receptors a v b 3 and a v b 5 in order to explore the compatability of the b-lactam linker strategy with a substantially more functionalized targeting module. Heterobifunctional linker 9 containing azide and NHS functionalities was prepared starting from triethyleneglycol 7 (Scheme 4). Triethylene glycol was bis-tosylated and converted to the corresponding bis-azide in excellent yield. The bis-azide was selectively reduced using an established procedure to give amino azide 8.
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Reaction of 8 with succinic anhydride and subsequent coupling with N-hydroxysuccinimide provided the desired heterobifinctional linker 9. Linker 9 was selectively conjugated with the e-amino group of the lysine moiety in the cyclic-RGD peptide (cyclo(ArgGly-Asp-D-Phe-Lys)) to give module 10. We also prepared linker module 12 (Scheme 5) in order to introduce the b-lactam functionality into our integrin targeting module.
Triethylene glycol 7 was treated with propargyl bromide in the presence of sodium hydride to afford a mixture of mono-and bispropargylated products that were separated by column chromatography. Mono-propargylated alcohol was then tosylated to afford tosyl alkyne 11. Compound 11 was reacted with ethyl 4-hydroxybenzoate in the presence of potassium carbonate in DMF to afford the alkynyl ester in 98% yield without need for purification. The ester was hydrolyzed using lithium hydroxide and converted to the acid chloride by treatment with neat thionyl chloride. The crude acid chloride was used immediately for the reaction with 2-azetidinone in the presence of n-butyl lithium to afford the desired heterobifunctional linker 12 in 51% isolated yield. The integrin targeting module 13 was synthesized in a copper (I)-catalyzed azide alkyne cycloaddition reaction of the heterobifunctional module 12 with the azido-targeting module 10 (Scheme 6). The resulting b-lactam-equipped targeting module was incubated with mAb 38C2 to provide chemically programmed (cp) antibody. Binding of the cp38C2 to human integrins a v b 3 and a v b 5 was confirmed by ELISA ( Fig. 2A and B) . 3, 7 Importantly, the chemically programmed antibody recognized the integrins on living cells: cp38C2 bound to human melanoma M21 cells that express both integrins a v b 3 and a v b 5 on their surface (Fig. 2C) . 7 As expected, unprogrammed catalytic antibody 38C2 did not bind to M21 cells.
In conclusion, we have prepared b-lactam-equipped targeting modules and demonstrated that these modules can be used to prepare chemically programmed antibodies. The modular strategy and use of bioorthogonal click chemistry for the preparation of b-lactam-equipped targeting modules allowed straightforward access to these valuable immunotherapeutics. Further studies of the therapeutic effect of targeting integrin a v b 3 and a v b 5 receptors with chemically programmed mAb 38C2 are underway and will be reported in the due course.
